Topiramate: A review of preclinical, pharmacokinetic, and clinical data

Clinical Therapeutics

Volumn 19, Issue 6, 1997, Pages 1294-1308

  Rosenfeld, William E ^a  

^a Compreh Epilepsy Care Ctr C ^*  (United States)

Author keywords

Antiepileptic drug; Partial onset seizure; Pharmacokinetics; Topiramate

Indexed keywords

AMPA RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; CARBAMAZEPINE; KAINIC ACID RECEPTOR ANTAGONIST; PHENOBARBITAL; PHENYTOIN; PLACEBO; TOPIRAMATE; VALPROIC ACID;

ATAXIA; CLINICAL TRIAL; COGNITIVE DEFECT; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG RESEARCH; EPILEPSY; HUMAN; PSYCHOMOTOR DISORDER; REVIEW; SODIUM CONDUCTANCE; SOMNOLENCE; SPEECH DISORDER; VERTIGO;

EID: 0031418448     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80006-9     Document Type: Review

References (35)

1. Rogawski MA, Porter RJ. Antiepileptic drugs: Pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev. 1990;42:223-286.
2. Maryanoff BE, Nortoy SO, Gardocki JF, et al. Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-ß-D-fructopyranose sulfumate and related compounds. J Med Chem. 1987;30:880-887.
3. Patsalos PN, Sander JWAS. Newer antiepileptic drugs: Towards an improved risk-benefit ratio. Drug Saf. 1994;11: 37-67.
4. Brown SD, Wolf HH, Swinyard EA, et al. The novel anticonvulsant topiramate enhances GABA-mediated chloride flux. Epilepsia. 1993;34(Suppl 2):122. Abstract.
5. White HS, Brown SD, Skeen GA, Twyman RE. The investigational anticonvulsant topiramate potentiates GABA-evoked currents in mouse cortical neurons. Epilepsia. 1995;36(Suppl 4):34. Abstract.
6. +-induced seizure discharges in cultured hippocampal neurons. Epilepsia. 1995;36(Suppl 4):38. Abstract.
7. Severt L, Coulter DA, Sombati S, DeLorenzo RJ. Topiramate selectively blocks kainate currents in cultured hippocampal neurons. Epilepsia. 1995;36(Suppl 4):38. Abstract.
8. Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: Preclinical evaluation of a structurally novel anticonvulsant. Epilepsia. 1994;35:450-460.
9. Harden CL. New antiepileptic drugs. Neurology. 1994;44:787-795.
10. Data on file, Robert Wood Johnson Pharmaceutical Research Institute.
11. Easterling DE, Zakszewski T, Moyer MD, et al. Plasma pharmacokinetics in topiramate, a new anticonvulsant, in humans. Epilepsia. 1988;29:662. Abstract.
12. Doose DR, Scott VV, Margul BL, et al. Multiple-dose pharmacokinetics of topiramate in healthy male subjects. Epilepsia. 1988;29:662. Abstract.
13. Bialer M. Comparative pharmacokinetics of the newer antiepileptic drugs. Clin Pharmacokinet. 1993;24:441-452.
14. Doose DR, Gisclon LG, Stellar SM, et al. The effect of food on the bioavailability of topiramate from 100-mg and 400-mg tablets in healthy male volunteers. Epilepsia. 1992;33(Suppl 3):105. Abstract.
15. Gisclon LG, Riffitts JM, Sica DA, et al. The pharmacokinetics (PK) of topiramate (T) in subjects with renal impairment (RI) as compared to matched subjects with normal renal function (NRF). Pharm Res. 1993;10(Suppl 10):S-397. Abstract.
16. Gisclon LG, Curtin CR, Sica DA, et al. The pharmacokinetics (PK) of topiramate (T) in subjects with end-stage renal disease undergoing hemodialysis. Clin Pharmacol Ther. 1994;55:196. Abstract PIII-56.
17. Rosenfeld WE, Doose DR, Walker SA, Reife RA. The steady-state pharmacokinetics of topiramate as adjunctive therapy in pediatric subjects with epilepsy. Epilepsia. 1995;36(Suppl 3):S158. Abstract.
18. Sachdeo RC, Sachdeo SK, Walker SA, et al. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia. 1996;37: 774-780.
19. Gisclon LG, Curtin CR, Kramer LD. The steady-state pharmacokinetics of phenytoin (Dilantin Kapseals® brand) and of Topamax® (topiramate) in male and female epileptic patients on monotherapy, and during combination therapy. Epilepsia. 1994;35(Suppl 8):54. Abstract.
20. Rosenfeld WE, Liao S, Kramer LD, et al. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia. 1997; 38:324-333.
21. Liao S, Palmer M. Digoxin and topiramate drug interaction study in male volunteers. Pharm Res. 1993;10(Suppl): S405. Abstract PPDM 8425.
22. Rosenfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia. 1997;38:317-323.
23. Faught E, Wilder BJ, Ramsay RE, and the Topiramate YD Study Group. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200, 400 and 600 mg daily dosages. Neurology. 1996;46:1684-1690.
24. Privitera M, Fincham R, Penry J, and the Topiramate YE Study Group. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600, 800 and 1000 mg daily dosages. Neurology. 1996;46:1678-1683.
25. Sharief M, Viteri C, Ben-Menachem E, et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res. 1996;25: 217-224.
26. Tassinari C, Michelucci R, Chauvel P, et al. Double-blind placebo-controlled trial of topiramate (600 mg/day) for the treatment of refractory partial epilepsy. Epilepsia. 1996;37:763-768.
27. Ben-Menachem R, Henriksen O, Dam M, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial epilepsy. Epilepsia. 1996;37:539-543.
28. Pledger G, Reife R, Lim P, Karim R. Overview of topiramate efficacy from adjunctive therapy trials. Epilepsia. 1995;36 (Suppl 3):150. Abstract.
29. Reife RA, Lim P, Pledger G. Topiramate: Side effect profile in double-blind studies. Epilepsia. 1995;36(Suppl 4):34. Abstract.
30. Edward KR, Kamin MT. The beneficial effect of slowing the initial titration rate of topiramate. Neurology. 1997;48(Suppl): A39. Abstract.
31. Fincham RW, Schottelius DD. Long-term therapy with topiramate in patients with partial seizures. Epilepsia. 1995;36(Suppl 4):56. Abstract.
32. Privitera M. Long-term efficacy and safety of topiramate. Epilepsia. 1995;36(Suppl 3):152. Abstract.
33. Ben-Menachem E. Long-term follow-up of patients treated with topiramate for partial seizures. Epilepsia. 1995;36(Suppl 3): 152. Abstract.
34. Wasserstein AG, Rak I, Reife RA. Nephrolithiasis during treatment with topiramate. Epilepsia. 1995;36(Suppl 3): 153. Abstract.
35. Rosenfeld WE, Holmes GB, Hunt TL, Schaefer P. Topiramate - effective dosing enhances potential for success. Epilepsia. 1992;33(Suppl 13):118. Abstract.